Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
XADAGO (Seqirus Pty Ltd)
Product name
XADAGO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
241 working days (255)
Active ingredients
safinamide mesilate
Registration type
NCE/NBE
Indication
XADAGO (film coated tablets) is indicated for the treatment of adult patients with fluctuating idiopathic Parkinson's disease (PD) as add-on therapy to a regimen that includes levodopa (L-Dopa).